Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Coca-Cola vs. Johnson & Johnson: The Safest Dividend on Wall Street Might Surprise You
Published: April 16, 2026 by: 24/7 Wall Street
Sentiment: Positive
Coca-Cola (NYSE:KO | KO Price Prediction) closed 2025 with steady organic growth and a 63rd consecutive dividend increase, while Johnson & Johnson (NYSE:JNJ) opened 2026 with accelerating pharmaceutical momentum and its own 64-year dividend streak intact.
Read More
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
Published: April 16, 2026 by: Zacks Investment Research
Sentiment: Positive
J&J targets double-digit growth by 2030 despite Stelara hit, banking on Innovative Medicine strength, MedTech gains and new launches.
Read More
These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results
Published: April 15, 2026 by: Benzinga
Sentiment: Positive
Johnson & Johnson (NYSE: JNJ) on Tuesday posted upbeat earnings for the first quarter.
Read More
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Published: April 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Johnson & Johnson's Spravato sales growth signals upside for psychedelics peers like AtaiBeckley
Published: April 14, 2026 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ)'s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales growth, with Jefferies analysts pointing to implications for companies such as AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) and peers developing next-generation mental health treatments. Spravato (esketamine nasal spray), which is approved for treatment-resistant depression (TRD), generated $468 million in global sales in the first quarter of 2026, representing a 46% increase year over year.
Read More
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results
Published: April 14, 2026 by: MarketBeat
Sentiment: Neutral
Johnson & Johnson's NYSE: JNJ price action entered consolidation in early March. While it may continue moving sideways or even pull back further, those moves are unlikely, given a convergence of factors.
Read More
Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today
Published: April 14, 2026 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson delivered a robust Q1, with revenues up nearly 10% YoY to $24.1bn and a raised full-year 2026 sales guidance above $100bn. JNJ's diversified portfolio—driven by double-digit growth in Innovative Medicines and strong growth in MedTech—positions it as "the cleanest growth story in healthcare." Most key products face minimal near-term patent risk, while new launches like icotrokinra, Rybrevant, and Inlexzo offer multibillion-dollar potential.
Read More
J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook
Published: April 14, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ tops Q1 earnings and sales estimates, lifts 2026 outlook as strong oncology and MedTech growth offset steep Stelara decline.
Read More
Johnson and Johnson Raises Dividend for 64th Consecutive Year
Published: April 14, 2026 by: 24/7 Wall Street
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) declared its 64th consecutive annual dividend increase on April 14, 2026, lifting its quarterly payout from $1.30 per share to $1.34 per share, a 3% increase.
Read More
Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off
Published: April 13, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ edges out LLY in a tight pharma showdown, backed by stronger valuation and stock performance despite Lilly's explosive GLP-1-driven growth.
Read More
Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
Published: April 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
JNJ approaches Q1 results with strong drug growth and MedTech momentum. However, rising biosimilar competition and pricing pressures cloud the outlook.
Read More
Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.
Published: April 08, 2026 by: Barrons
Sentiment: Positive
As the company heads into its first-quarter earnings report, the narrative has changed from last year's struggles.
Read More
$10,000 to Invest? Coca-Cola or Johnson & Johnson- One Stock Is More Reliable
Published: April 06, 2026 by: 24/7 Wall Street
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both closed out 2025 with Q4 earnings and have raised dividends for 63 consecutive years.
Read More
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why You Don't Bet Against This Dividend King
Published: March 31, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner.
Read More
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
Published: March 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
5 Defensive Stocks to Buy Amid Market's Recent Bloodbath
Published: March 30, 2026 by: Zacks Investment Research
Sentiment: Positive
DUK, ETR, STZ, KO and JNJ emerge as defensive picks as market volatility spikes, offering stability through dividends, low beta, and steady growth strategies.
Read More
Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results.
Read More
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
Published: March 24, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and legal risks.
Read More
Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet
Published: March 24, 2026 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
J&J Expands New Drug Portfolio With Icotyde's FDA Approval
Published: March 19, 2026 by: Zacks Investment Research
Sentiment: Positive
J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.
Read More
The Big 3: ORCL, JNJ, SBUX
Published: March 19, 2026 by: Schwab Network
Sentiment: Neutral
Dan Deming urges investors to stay nimble as markets grapple with crude oil, gold, and silver volatility. That said, he sees trading opportunities available in the markets.
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: March 19, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company
Published: March 19, 2026 by: Forbes
Sentiment: Neutral
Question: What caused JNJ stock to rise 70% since early 2025?
Read More
TrumpRx lists many medicines at prices higher than paid in UK
Published: March 18, 2026 by: Reuters
Sentiment: Negative
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Published: March 18, 2026 by: CNBC
Sentiment: Positive
Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde. Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi.
Read More
J&J or Merck? Key Factors Investors Must Weigh Right Now
Published: March 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson JNJ and Merck MRK are among the top U.S. healthcare giants, making them ideal candidates for a direct comparison.
Read More
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Published: March 05, 2026 by: PRNewsWire
Sentiment: Neutral
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit HORSHAM, Pa., March 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor …
Read More
Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026
Published: March 04, 2026 by: 24/7 Wall Street
Sentiment: Positive
Volatility is again picking up, and it's a good idea to focus more on safety.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100